Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Stock
Equities
600329
CNE000001808
Pharmaceuticals
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
34.37 CNY | +2.26% | +3.77% | +2.14% |
Sales 2024 * | 9.05B 1.25B 1.71B | Sales 2025 * | 9.96B 1.38B 1.88B | Capitalization | 22.2B 3.07B 4.19B |
---|---|---|---|---|---|
Net income 2024 * | 1.17B 162M 221M | Net income 2025 * | 1.4B 193M 264M | EV / Sales 2024 * | 2.45 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 2.23 x |
P/E ratio 2024 * |
22.6
x | P/E ratio 2025 * |
18.9
x | Employees | 4,619 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 31.08% |
1 day | +2.26% | ||
1 week | +3.77% | ||
Current month | +23.19% | ||
1 month | +22.23% | ||
3 months | +19.13% | ||
6 months | +7.74% | ||
Current year | +2.14% |
Managers | Title | Age | Since |
---|---|---|---|
Lei Wang
CEO | Chief Executive Officer | 53 | 22-08-21 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
42 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ping Zhang
BRD | Director/Board Member | 55 | 19-09-29 |
Yoke Pheng Liew
BRD | Director/Board Member | 68 | 20-06-04 |
Hong Zhou
CTO | Chief Tech/Sci/R&D Officer | 54 | 12-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +2.67% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 34.37 | +2.26% | 8,513,755 |
24-04-25 | 33.61 | +0.09% | 5,878,664 |
24-04-24 | 33.58 | +1.21% | 6,715,129 |
24-04-23 | 33.18 | -0.69% | 8,390,897 |
24-04-22 | 33.41 | +0.88% | 10,611,810 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+2.14% | 3.1B | |
+35.04% | 5.92B | |
-15.13% | 4.51B | |
-9.75% | 3.15B | |
-6.82% | 2.42B | |
+47.87% | 1.97B | |
-7.89% | 1.68B | |
+0.09% | 1.65B | |
-12.97% | 1.53B | |
+33.40% | 1.38B |
- Stock Market
- Equities
- 600329 Stock